|
|
Volumn , Issue , 2013, Pages
|
|
Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer
a a a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERBB2 PROTEIN, HUMAN;
LAPATINIB;
MONOCLONAL ANTIBODY;
PROTEIN KINASE INHIBITOR;
QUINAZOLINE DERIVATIVE;
TRASTUZUMAB;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
BREAST NEOPLASMS;
DRUG EFFECTS;
DRUG RESISTANCE;
ENZYMOLOGY;
FEMALE;
HUMAN;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
PATHOLOGY;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
ANIMALS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
DRUG RESISTANCE, NEOPLASM;
FEMALE;
HUMANS;
MOLECULAR TARGETED THERAPY;
NEOADJUVANT THERAPY;
PROTEIN KINASE INHIBITORS;
QUINAZOLINES;
RECEPTOR, ERBB-2;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
|
|
EID: 84946208014
PISSN: None
EISSN: 15488756
Source Type: Journal
DOI: 10.1200/EdBook_AM.2013.33.e2 Document Type: Review |
|
Times cited : (19)
|
|
References (0)
|